ASHLEY ROY: Open Payments
NPI 1568241214 · AUGUSTA, ME. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$809 in 26 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $227 · 2025 $809
Food & beverage: $809
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 6 | $214 |
| Madrigal Pharmaceuticals | 5 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $144 |
| Janssen Biotech, Inc. | 1 | $108 |
| Ipsen Biopharmaceuticals, Inc | 2 | $61 |
| ABBVIE INC. | 2 | $48 |
| GENZYME CORPORATION | 1 | $26 |
| Ardelyx, Inc. | 1 | $21 |
| Novo Nordisk Inc | 1 | $16 |
Products named: REZDIFFRA, ENTYVIO, Livdelzi, TREMFYA, IQIRVO, RINVOQ, DUPIXENT, IBSRELA.
Industry payments across ME — which companies pay providers there.
